Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | acetylcholinesterase | 0.0312 | 1 | 1 |
Mycobacterium ulcerans | DNA gyrase subunit B | 0.0086 | 0 | 0.5 |
Trichomonas vaginalis | DNA topoisomerase II, putative | 0.0262 | 0.7806 | 0.5 |
Echinococcus multilocularis | acetylcholinesterase | 0.0312 | 1 | 1 |
Plasmodium vivax | DNA topoisomerase II, putative | 0.0262 | 0.7806 | 1 |
Trypanosoma brucei | DNA topoisomerase II alpha, putative | 0.0236 | 0.6635 | 1 |
Echinococcus multilocularis | carboxylesterase 5A | 0.0312 | 1 | 1 |
Brugia malayi | Carboxylesterase family protein | 0.0312 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0312 | 1 | 1 |
Loa Loa (eye worm) | acetylcholinesterase 1 | 0.0312 | 1 | 1 |
Loa Loa (eye worm) | carboxylesterase | 0.0312 | 1 | 1 |
Toxoplasma gondii | DNA topoisomerase 2, putative | 0.0262 | 0.7806 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0312 | 1 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0236 | 0.6635 | 1 |
Mycobacterium tuberculosis | DNA gyrase (subunit B) GyrB (DNA topoisomerase (ATP-hydrolysing)) (DNA topoisomerase II) (type II DNA topoisomerase) | 0.0086 | 0 | 0.5 |
Echinococcus granulosus | acetylcholinesterase | 0.0312 | 1 | 1 |
Leishmania major | DNA topoisomerase ii | 0.0236 | 0.6635 | 1 |
Onchocerca volvulus | Putative DNA topoisomerase 2, mitochondrial | 0.019 | 0.4608 | 0.5 |
Schistosoma mansoni | family S9 non-peptidase homologue (S09 family) | 0.0312 | 1 | 1 |
Chlamydia trachomatis | DNA gyrase subunit B | 0.0142 | 0.2486 | 1 |
Trypanosoma brucei | DNA topoisomerase II beta, putative | 0.0236 | 0.6635 | 1 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.019 | 0.4608 | 0.5 |
Loa Loa (eye worm) | TOPoisomerase family member | 0.0262 | 0.7806 | 0.7474 |
Treponema pallidum | DNA gyrase, subunit B (gyrB) | 0.0086 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0176 | 0.3978 | 0.3067 |
Echinococcus granulosus | carboxylesterase 5A | 0.0312 | 1 | 1 |
Giardia lamblia | DNA topoisomerase II | 0.0251 | 0.7293 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0176 | 0.3978 | 0.3067 |
Onchocerca volvulus | DNA topoisomerase 2 homolog | 0.019 | 0.4608 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | DNA gyrase, topoisomerase II, B subunit, GyrB | 0.0086 | 0 | 0.5 |
Entamoeba histolytica | DNA topoisomerase II, putative | 0.0262 | 0.7806 | 0.5 |
Plasmodium falciparum | DNA topoisomerase 2 | 0.0262 | 0.7806 | 1 |
Trypanosoma cruzi | DNA topoisomerase II, putative | 0.0236 | 0.6635 | 1 |
Echinococcus granulosus | acetylcholinesterase | 0.0312 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (functional) | = 4.63 uM | Cytotoxicity against CAOV-3 human tumor cell lines | ChEMBL. | No reference |
IC50 (functional) | = 8.79 uM | Cytotoxicity against DLD-1 human tumor cell lines | ChEMBL. | No reference |
IC50 (functional) | = 8.79 uM | Cytotoxicity against DLD-1 human tumor cell lines | ChEMBL. | No reference |
IC50 (functional) | = 13.03 uM | Cytotoxicity against L1210 tumor cell lines in mice | ChEMBL. | No reference |
IC50 (functional) | = 13.03 uM | Cytotoxicity against L1210 tumor cell lines in mice | ChEMBL. | No reference |
IC50 (functional) | = 23.31 uM | Cytotoxicity against A-172 human tumor cell lines | ChEMBL. | No reference |
IC50 (functional) | = 23.31 uM | Cytotoxicity against A-172 human tumor cell lines | ChEMBL. | No reference |
IC50 (functional) | = 47.76 uM | Cytotoxicity against KATO-III human tumor cell lines | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 | ||
Mus musculus | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.